Services to COVID-19 vaccine developers

Published 18 March 2020

From Transvac initiative

TRANSVAC is dedicated to accelerate vaccine candidates across the R&D pipeline, by offering services to vaccine developers in academic and industry settings.

TRANSVAC services cover all aspects of vaccine development, for any target disease, for prophylactic, therapeutic, human and veterinary vaccines:

?Cross-platform screening and optimisation
? Analytical Services
? Adjuvants and delivery systems
⚗ Pre-clinical GLP Production Services
? GMP Production Services (Paid)
⚛ Structural Biology
? Immunocorrelates and Systems Biology
? Animal Models
? Clinical Trial support


COVID-19 vaccine development


Researchers developing vaccine candidates against COVID19 can also benefit from TRANSVAC2 services, namely but not exclusively:

Animal models

  • CEA
  • BPRC
  • IRTA
  • CReSA Centre de Recerca en Sanitat Animal and Helmholtz Centre for Infection Research (HZI)

Adjuvant formulation

  • HZI

Clinical Trial Support

  • ECRIN (European Clinical Research Infrastructure Network)

Regulatory support

  • EATRIS and European Vaccine Initiative

You can visit for more information.